Similar articles

• Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?

  Altagracia-Martínez M, Kravzov-Jinich J, Guadarrama-Atrizco MD, Rubio-Poo C, Wertheimer AI. Altagracia-Martínez M, et al. Res Social Adm Pharm. 2006 Mar;2(1):22-37. doi: 10.1016/j.sapharm.2005.10.001. Res Social Adm Pharm. 2006. PMID: 17138499
• Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?

  Moran A, Goldman L. Moran A, et al. Nat Clin Pract Cardiovasc Med. 2008 Oct;5(10):606-7. doi: 10.1038/ncpcardio1309. Epub 2008 Aug 12. Nat Clin Pract Cardiovasc Med. 2008. PMID: 18695697
• [Fully possible to reduce the costs of hypertension treatment].

  Wettermark B, Angman A, Hjemdahl P. Wettermark B, et al. Lakartidningen. 2009 Jun 3-9;106(23):1558-62. Lakartidningen. 2009. PMID: 19583013 Review. Swedish. No abstract available.
• Renin-angiotensin system and cardiovascular risk.

  Mascitelli L, Pezzetta F. Mascitelli L, et al. Lancet. 2007 Jul 7;370(9581):24; author reply 24-5. doi: 10.1016/S0140-6736(07)61035-6. Lancet. 2007. PMID: 17617259 No abstract available.
• Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?

  Ghanem FA, Movahed A. Ghanem FA, et al. Rev Cardiovasc Med. 2005 Fall;6(4):206-13. Rev Cardiovasc Med. 2005. PMID: 16379016 Review.